Buspirone for Opioid Tapering

Completed · Phase 1 · Has a placebo group

Conditions studied: Opioid-Related Disorders, Dependency (Psychology), Pain, Chronic, Opiate Withdrawal Syndrome

In brief

This is a pilot study to collect preliminary data to support a grant application. The goal of the study is to evaluate whether the Food and Drug Administration (FDA)-approved and generically-available medication buspirone reduces symptoms of opioid withdrawal among patients undergoing a clinically-indicated and supervised taper from their opioid pain medications. This is premised on strong preclinical scientific support but has not yet be well-examined in humans.

Key facts

Study ID

NCT03521960

Run by

Johns Hopkins University

People needed

18

Starts

2018-05-30

Expected to finish

2020-06-30

Last updated by the study team

2020-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be at least 18 years old
• Be undergoing taper of prescribed opioid pain medications at the study site

You may not qualify if…

• Being pregnant or breastfeeding
• Past 7-day use of grapefruit juice or other strong Cytochrome (CYP) P450 inhibitors or inducers
• Have medical or psychiatric condition that is contraindicated with buspirone administration
• Current suicidality as assessed by clinic staff or the Columbia Suicide Severity Rating Scale

Where it is running

• Johns Hopkins University — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.